Navigation Links
Monogram Announces 2008 Second Quarter Financial Results
Date:7/29/2008

ed Merriweather, Monogram's Chief Financial Officer. "Gross margin on product revenues for the second quarter was 54%."

The Company had approximately $26.9 million in cash, cash equivalents and short-term investments at June 30, 2008. Cash used in operations for the first six months of 2008 was $8.4 million.

HIV Tropism and Resistance Testing

Recent significant developments in Monogram's HIV business include:

-- Introduction in June of sensitivity enhancements to Trofile enabling the identification of X4 virus present at a level as low as 0.3% of the total viral population, a thirty-fold increase in sensitivity.

-- Presentation in June, at the Drug Resistance Workshop in Sitges, Spain, of data providing clinical validation of optimized patient selection with the enhanced assay format.

-- Establishment of coverage for Trofile by New York and California state Medicaid programs.

-- Announcement of the availability August 4 of the PhenoSense Integrase assay for assessing resistance to the integrase class of HIV drugs.

-- Extension of Trofile's availability outside of the U.S. to thirteen European countries, Canada, Brazil and Argentina.

"Selecting the right treatment regimens for HIV patients is critical, not only to assure that each individual drug is appropriate for the individual patient but also to make sure that the entire regimen is as robust as possible to protect the other drugs in the patient's regimen from unnecessary exposure to the development of resistance," said William Young, Monogram Chief Executive Officer. "The implementation of enhanced sensitivity in Trofile and the introduction of our resistance test for the integrase class of HIV drugs further extend Monogram's industry-leading portfolio of assays for guiding HIV therapy decisions."

HERmark(TM) Breast Cancer Assay

Recent significant developments for Monogram's HERmark Breast Cancer Assay include:

-- Presentation by
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... these particular arguments against the policy, put forward by ... the first country in the world to introduce standardised ... Ireland, and the UK are currently considering similar legislation. ... policy would deter people from buying their tobacco from ... of cheap products sourced from Asia, and increase the ...
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... Millennium Treatment Group recently announced a new goal. ... Millennium Treatment Group is working to close it, providing more ... According to the National Survey on Drug Use and ... have benefited from treatment for drug and/or substance abuse, but ... that there is a large treatment gap in the United ...
(Date:8/28/2014)... Aug. 28, 2014 (HealthDay News) -- Arguments between parents ... study indicates. Parents in more than 200 families ... days. At the end of each day, mothers and ... relationship with their children. On days when parents ... with their children were also strained, according to the ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
Breaking Medicine News(10 mins):Health News:Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Kids Dental July 1, LANSING, Mich., June 12 ... of Community Health (MDCH) today,announced an expansion of the ... Genesee and Saginaw counties, bringing the total,number of Michigan ... effect July 1, 2008., "We are extending needed ...
... anticancer drug sensitivity found in translation , The ... large problem. In some cases, such resistance is associated ... translation, which is central to the generation of proteins. ... McGill University, Montreal, have identified a drug that can ...
... June 12 MEDRAD, INC., has signed ... Solutions,a fully owned subsidiary of Siemens Medical ... care providers to inject Fluorodeoxyglucose,(FDG) for Positron ... innovative, new way. The partnership will leverage,MEDRAD,s ...
... molecular machinery is pointing toward new drugs and treatments ... era of personalized medicine, in which doctors aim to ... the right patient, also brings concerns about genetic privacy, ... , The American Association for the Advancement of Science ...
... Protection Act Will End Pre-Existing Condition,Limitations For Children ... Conditions, WASHINGTON, June 12 The National ... dedicated,to the mission of creating avenues of improved ... at the state and federal levels -- today,praised ...
... to track down source of salmonella-contaminated tomatoes , , ... ongoing outbreak of salmonella-contaminated tomatoes as a backdrop, ... and Drug Administration has failed to meet its ... supply. , Investigators for the Government Accountability Office ...
Cached Medicine News:Health News:Dental Services Expand to Serve More Than 280,000 Michigan Children 2Health News:JCI online early table of contents: June 12, 2008 2Health News:JCI online early table of contents: June 12, 2008 3Health News:JCI online early table of contents: June 12, 2008 4Health News:JCI online early table of contents: June 12, 2008 5Health News:JCI online early table of contents: June 12, 2008 6Health News:JCI online early table of contents: June 12, 2008 7Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 3Health News:Congressional Report Criticizes FDA for Food Safety 2Health News:Congressional Report Criticizes FDA for Food Safety 3Health News:Congressional Report Criticizes FDA for Food Safety 4Health News:Congressional Report Criticizes FDA for Food Safety 5
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Markets to 2020 - Novel Therapeutic ... Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics in ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
(Date:8/28/2014)... , Aug. 28, 2014  Rx Safes, Inc., ... announced that it is waging a new war on ... national media campaign. More than 2,500 children ... time and these drugs are easily accessed from unsecured medicine ... drug dealers on the streets, Rx Safes will address ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Rx Safes, Inc. Announces New War On Drugs 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: